Opinion|Videos|April 4, 2025
De-Escalating Treatment Plans With Gene Expression Profiling in an 80-Year-Old Man With SCC
Author(s)David Cotter, MD, PhD
An expert discusses their impressions of the case, classifying the patient’s risk based on the clinical presentation of the lesion, and outlines treatment recommendations without knowing the 40-gene expression profile (GEP) information, including whether adjuvant therapy (ART) would be recommended. The expert also shares how to discuss 40-GEP testing with patients and reassure them that accurate risk levels are crucial for receiving optimal treatment.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are your impressions of this case? Based on the clinical presentation of the lesion, how would you classify the patient’s risk?
- Without knowing the 40-GEP information, what would your treatment recommendation be? Would you recommend ART for this patient?
- How do you discuss 40-GEP testing with your patients? How can you best reassure patients that an accurate risk level is critical to receiving optimal treatment?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis
3
Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older
4
Introducing Dermatology Times NP/PA Connect
5